Company news
Aethlon Medical, Inc. news in 2024
Aethlon Medical, Inc.'s news releases, calls and decks from 2024, newest first.
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
December 19, 2024
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
November 12, 2024
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
November 10, 2024
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024
November 5, 2024
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
October 7, 2024
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
September 18, 2024
Aethlon Medical to Present at Virtual Investor Conferences in September
September 16, 2024
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
September 15, 2024
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
September 12, 2024
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
August 26, 2024
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
August 13, 2024
Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial
August 11, 2024
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024
August 5, 2024
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
June 26, 2024
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
June 20, 2024
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
June 17, 2024
Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
June 2, 2024
Aethlon Medical Announces Pricing of $4.7 Million Public Offering
May 14, 2024
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
May 9, 2024
Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
February 20, 2024
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
February 6, 2024
Calls in 2024
Decks in 2024
- Investor Presentation (September 2024)
Investor deck · 26 slides · September 2024
- Investor Presentation (May 2024)
Investor deck · 22 slides · May 9, 2024
- Investor Presentation (April 2024)
Investor deck · 22 slides · April 2024